TokenPost·
Lineage Cell Therapeutics Adds HUNT1, Projects Funding Into Q2 2028
The company reported $45.2 million in cash, cash equivalents and marketable securities. HUNT1 is an enrolling Phase Ib/IIa program for Huntington’s disease.
More news
- TokenPostDarkfost Says Bitcoin’s Extreme Undervaluation Appeared in 3.4% of Its History
- TokenPostWhale Withdraws $19.91 Million in Ether From Binance on Nov. 13
- Crypto BriefingBitcoin risks falling to $62,000 as Fed hike odds climb, risk appetite weakens: Bitget Wallet analyst
- TokenPostMetaplanet Releases Third-Quarter Results for Fiscal 2026
- TokenPostBitcoin Falls 6.48% as Crypto Market Shrinks to $2.31 Trillion
- TokenPostWallet’s Ether (ETH) Position Shows $11.342 Million Unrealized Loss